Kodiak Sciences Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing treatments for retinal diseases. The quarter ended March 31, 2022; financial results are compared with the three months ended March 31, 2021. Kodiak had no approved products and generated no product revenue.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $76.2 million | $40.3 million |
| General and administrative expense | $19.6 million | $10.2 million |
| Total operating expenses / operating loss | $95.8 million | $50.6 million |
| Net loss | $95.7 million | $50.4 million |
| Net loss per share, basic and diluted | $1.83 | $0.98 |
| Cash used in operating activities | $43.2 million | $34.6 million |
| Cash, cash equivalents and restricted cash at period end | $678.1 million | $926.8 million |
At March 31, 2022, cash and cash equivalents were $671.7 million, current assets were $682.2 million, current liabilities were $76.3 million, and stockholders’ equity was $597.4 million. Total liabilities were $252.9 million, including a $100.0 million liability related to the sale of future royalties and operating lease liabilities. The filing reports no product margins; Kodiak had no product revenue. The company said available cash and cash equivalents should cover anticipated operating and capital needs for at least 12 months following the May 10, 2022 filing date.
Material changes versus the prior comparable period
- Net loss increased by $45.3 million, while operating expenses rose by $45.2 million. R&D expense increased $35.8 million, primarily from KSI-301 clinical and manufacturing work, pipeline activity, and personnel costs. G&A rose $9.4 million.
- Stock-based compensation increased to $28.1 million from $9.9 million, including incremental expense associated with the 2021 Long-Term Performance Incentive Plan.
- Operating cash use increased to $43.2 million from $34.6 million. Investing activities used $18.3 million, primarily for property and equipment, compared with $9.2 million provided in Q1 2021.
- Cash and cash equivalents declined $59.8 million from December 31, 2021. Accumulated deficit reached $653.9 million.
Outlook, development, risks and unusual items
- Management expects R&D spending to increase substantially as it advances Phase 3 trials, seeks regulatory approvals, and prepares for potential commercialization. G&A is also expected to grow. No specific financial guidance was provided.
- KSI-301 is Kodiak’s lead clinical candidate and is being studied in five Phase 3 trials. The company reported that its prior Phase 2b/3 wet AMD study did not meet the primary endpoint of non-inferior visual-acuity gains for extended dosing versus aflibercept every eight weeks. Kodiak modified protocols in ongoing DME and wet AMD trials to address potential undertreatment.
- At the filing date, Kodiak expected BEACON RVO top-line data in August 2022; GLEAM and GLIMMER DME and DAYLIGHT wet AMD data in mid-2023; and GLOW NPDR enrollment to be completed in 2022. These were forward-looking expectations, not results.
- COVID-19-related lockdowns in China impaired recruitment and operations; Kodiak paused clinical development activities in China. The company said missed visits were under 5% across ongoing studies but warned that pandemic effects could still disrupt trials and supply.
- The Lonza manufacturing facility dedicated to KSI-301 achieved mechanical completion in March 2022. Kodiak’s estimated capital contribution was approximately CHF 75 million, of which CHF 35 million had been paid. Potential commercial-supply manufacturing payments of approximately CHF 150 million may be incurred from 2022 through 2029.
- Key risks include clinical failure or delay, regulatory uncertainty, manufacturing scale-up and third-party supply dependence, competition, and the need for future financing. The company said it had no material legal proceedings known to management. Disclosure controls were deemed effective as of March 31, 2022.
Most important facts for investors to verify
- Subsequent clinical data and whether protocol changes address the wet AMD undertreatment concern.
- Actual trial timelines, enrollment, safety and efficacy results, and any regulatory feedback affecting the planned BLA strategy.
- Cash burn, capital spending, stock-based compensation, and whether cash runway remains consistent with management’s estimate.
- Lonza facility performance, remaining manufacturing commitments, and the cost and readiness of commercial-scale supply.
- Whether China-related disruption, COVID-19, competition, or other supply-chain constraints materially alter development plans.